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Abstract
Background: To evaluate radiographic progression of patients with new-onset juvenile idiopathic arthritis (JIA) in
response to an early, tightly-controlled, treatment-to-target.
Methods: Patients with JIA participating in the BeSt-for-Kids-study, randomized to 3 treatment strategy arms, were
eligible if at least 1 conventional wrist-radiograph was available. Bone damage as reflected by carpal length was
assessed using the Poznanski-score. The BoneXpert-method was used to determine the Bone Age (BA, > 5 years)
and bone mineral density (BMD) of the wrist. These scores were evaluated over time and compared between the
treatment arms and mean JADAS10-score using linear mixed models corrected for age and symptom duration.
Results: In 60 patients, 252 radiographs were analysed. Baseline age and symptom duration were different between
the arms. No difference in comparison to the healthy reference population was found at baseline for the Poznanski-
score (IQR varying from − 0,82; 0.68), nor for BA (varying from − 0.88 to 0.74). Baseline BMD was statistically significantly
lower in arm 3 (initial treatment with etanercept and methotrexate) (− 1.48; − 0.68) compared to arm 1 (− 0.84; − 0.04)
and arm 2 (− 0.93; 0.15). After treatment to target inactive disease, the Poznanski-scores and the BA remained clinically
unchanged, while the BMD in arm 3 improved (p < 0.05 vs arm 1).
Conclusions: Recent-onset JIA patients, treated-to-target aimed at inactive disease, showed no signs of radiographic
wrist damage (Poznanski-score, BA or BMD) either at baseline or at follow-up, irrespective of treatment arm. A lower
BMD at baseline in arm 3, initially treated with methotrexate and etanercept, improved significantly after treatment.
Trial registration: NTR, NL1504 (NTR1574). Registered 01-06-2009.
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Background
Juvenile idiopathic arthritis (JIA) is a potentially chronic
disease that comprises 7 categories of childhood arthritis
of unknown cause, that persists for more than 6 weeks
and starts before the age of 16 [1]. Osteopenia, bony
deformity, erosions, and cartilage loss in carpalia, result-
ing in carpus shortening, can be complications of in-
flammation in JIA patients [2–5]. Previous studies have
shown that early damage on conventional radiography is
correlated with functional deterioration and radiographic
progression after 5 years [2, 5, 6], and also with smaller
chances to achieve clinical remission [7]. Monitoring of
radiographic damage progression is therefore important
to evaluate treatment effect and predict prognosis. Since
joint damage is assumed to be the result of ongoing in-
flammation, reaching inactive disease as early as possible
and thereby preventing structural joint damage and con-
sequently limitations in physical functioning, should be
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the goal of treatment [8]. This is facilitated by the avail-
ability of new effective disease modifying antirheumatic
drugs (DMARDs) [9]. In accordance, current JIA treat-
ment recommendations focus on earlier introduction of
DMARDs aiming to achieve remission or at least low
disease activity [8, 9].
We have recently performed a randomized clinical trial
using the treatment-to-target approach in recent-onset
JIA patients, comparing 3 strategy-arms with different
initial and subsequent treatment steps, aiming at inactive
disease, including tapering and stopping DMARD therapy
[10, 11]. In this population we studied radiographic wrist
damage using the Poznanski-score, at baseline and evalu-
ated whether damage occurred or recovered with the
abrogation of inflammation in the 3 strategy-arms. In
addition we used the BoneXpert-method to determine the
Bone Age (BA) and Bone Mineral Density (BMD) as
markers for joint damage [12].
Methods
Patient selection
The Best-for-Kids-study (NTR 1574), a multicenter
randomized single-blinded clinical trial, was designed
to investigate the effectiveness of three different treatment-
strategies in newly diagnosed patients with the following
JIA categories: oligoarticular JIA, rheumatoid factor (RF)
negative polyarticular JIA and juvenile psoriatic arthritis.
DMARD-naive patients with a disease duration of less than
18months were randomized to one of the three treatment
arms.
Patients in arm 1 were treated with initial monotherapy
with methotrexate (MTX) or sulfasalazine (SSZ); patients
in arm 2 were treated with initial MTX and prednisone
bridging and patients in arm 3 were initially treated with
etanercept and MTX. Patients were treated to target,
aimed at inactive disease, with three-monthly assessments.
If predefined targets of suppression of inflammation were
not met, treatment was intensified, as can be seen in Fig. 1,
with subsequent treatment-steps, including etanercept
also in arm 1 and 2. In case of at least 6months of inactive
disease, treatment was tapered. The current sub-analysis
was done in all patients who had radiographs of one or
both hands obtained at study inclusion (with a range of
maximum 4months before) or at any follow-up visit up
to 40 months. Radiographs of hands and wrists were
encouraged at baseline, year 1 and year 2. In practice,
physicians were reluctant to do this if there was no
local arthritis. Juvenile Arthritis Disease Activity Score
(JADAS)10-scores were available from all the patients
[11]. To investigate the effect of the relatively fast chan-
ging disease activity on slower changing radiological
outcome parameters, we have used mean JADAS10-
scores over 2 years’ time as a predictor for the radio-
logical outcomes.
The BeSt-for-Kids-study was approved by the Institu-
tional Review Board at Leiden University Medical Center
and written informed consent was obtained from all par-
ticipants before enrollment.
Radiographic scoring
All radiographs were anonymized and randomized by an
independent computer-technician, and then evaluated
using two different scoring methods: the Poznanski-
score [13] and the BoneXpert-method. When radio-
graphs of both wrists were available, scores of both
wrists were included. The Poznanski-score was used to
measure carpal size, and was calculated as the mean
score of 2 independent readers (DS and WB), who were
unaware of clinical data. Open growth plates are neces-
sary to determine the Poznanski-score. The radiometa-
carpal length (RM, defined as the line from the mid-
growth plate of the radius to the center of the proximal
end of the third metacarpal) and the length of the sec-
ond metacarpal (M2, defined as the maximum length of
the second metacarpal as defined by Garn [14]) were
measured, in millimeters using RadiAnt DICOM viewer
version 2.2.8, as shown in Fig. 2. Poznanski’s gender-spe-
cific formulas were used to calculate the expected RM
for the observed M2 [13]. The difference between ex-
pected and measured RM was then calculated and con-
verted into a Z-score [13], which represents the number
of standard deviations that the observed RM diverges
from the expected RM. A negative Z-score indicates de-
layed growth in the radiometacarpal bones with loss of
cartilage or loss of joint space as potential causes,
whereas a positive Poznanski-score may indicate growth
acceleration, a phenomenon thought to be caused by
early ossification of carpal bones under influence of
chronic hyperemia and inflammation [15]. Radiographic
bone damage progression was determined by calculating
the change in Z-score between the baseline and follow-
up radiographs.
Next, all radiographs were imported as DICOM-files
in the BoneXpert-software for automatic assessment of
the BA (using the average Greulich and Pyle bone age
[16]), and BMD (BoneXpert Version 2.1.0.12; Visiana,
Holte, Denmark). The software generates Z-scores of
the BA computed relative to provided scores of healthy
children of equal gender, age (> 5 years) and ethnicity.
A negative Z-score for BA reflects a delayed bone matur-
ation [12, 17] whereas a positive Z-score reflects enhanced
focal maturation, also possible due to inflammation [15].
The BMD is automatically determined by measuring the
amount of cortical bone in the shafts of metacarpal 2–4.
The Z-score of BMD is computed compared to provided
scores in healthy children of the same bone age and
gender. A negative Z-score indicates a diminished BMD.
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For the Z-scores, the normal population has a normal
(Gaussian) distribution around 0.
Statistical analyses
The single measure intra-class correlation coefficient
(ICC) and Bland-Altman plots with 95% Confidence
Interval (CI) were used to determine the agreement of
measurements of Poznanski between the two observers
and to determine the inter-reader reliability. Baseline
characteristics were compared using one-way analysis of
variance, Kruskal-Wallis tests or Pearson Chi-square tests,
as appropriate. Linear mixed model (LMM) analyses were
performed to evaluate the Z-scores of the Poznanski-
score, Bone Age and BMD over time between the 3 treat-
ment groups. LMM was also used to evaluate the different
Z-scores over time for the mean JADAS-10 score over 2
years’ time, since we assumed that average disease activity
over 2 years’ time could have an effect on slower changing
variables like Poznanski score, Bone Age and BMD. We
assumed a multilevel structure of measurements over time
(level 1), nested within hands (left or right, level 2), nested
within patients (level 3), and added a random intercept
and slope to take into account correlations of measure-
ments performed within the same hand within the same
patient and differences in time periods between the differ-
ent radiographs. For the Poznanski-score, the model was
adjusted for the potential baseline confounders age and
duration of symptoms. Since the BA and BMD account
for age in itself, the models for BA and BMD were ad-
justed for duration of symptoms only. Multiple imputation
using package mice in software package R was used to
deal with missing values for symptom duration and
JADAS10-score, with n = 10 imputed data sets [11].
For all statistical analyses a p-value< 0.05 was considered
statistically significant. A deviation of > 1 in Z-score, indi-
cating a deviation >1SD from the mean in a normal popu-
lation, was arbitrarily defined as clinically relevant [17].
Statistical analyses were performed with SPSS version 23
software (SPSS, Chicago, IL., USA) and Stata SE version
14 (StataCorp LP).
Fig. 1 The three treatment strategies compared in the BeSt for Kids study. Flow diagram of the three treatment strategies compared in the
BeSt for Kids study; Revised diagnosis were localized scleroderma with arthritis (arm 1) and polyarteritis nodosa (arm 3). See patients and
methods section for description of treatment groups. FU = follow-up, SSZ = sulfasalazine, MTX = methotrexate, ETN = etanercept,
po = orally, sc = subcutaneous
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Results
Patients
Baseline characteristics of the included patients are pre-
sented in Table 1. Patients in arm 3 were younger and
had longer symptom duration than patients in arm 1
and 2. Nine patients with radiographs initially did not
have wrist arthritis, six patients never had wrist arthritis
clinically.
Of the original 94 patients included in the BeSt-for-
Kids cohort, 75 patients had at least 1 hand radiograph
available. Overall, 268 radiographs were available. Six-
teen radiographs, made outside the selected time frame,
were left out, leaving 252 radiographs (n = 127 of the left
hand and n = 125 of the right hand). Of these 92 (in 47
patients) were taken at baseline (with a window of 4
months before and 3month after inclusion) and 160 (in
52 patients, 27 patients had more than 2 radiographs)
during follow-up. Fourteen patients had closed growth
plates at baseline and were left out, one patient left the
study due to changing diagnosis and was not included in
the current analysis [18]. A flow chart of the patient se-
lection process is provided (Additional file 1).
Sixty patients with 252 radiographs (85 in arm 1, 79 in
arm 2 and 88 in arm 3) were eligible for scoring by the
Poznanski-method and BMD. For analysis of the BA 196
radiographs of 49 patients (65 in arm 1, 67 In arm 2, 64
in arm 3) were eligible, while 56 X-rays (20 in arm 1, 12
in arm 2 and 24 in arm 3) of 11 patients could not be
scored because patients’ age was < 5 years.
The Poznanski-score
For the Poznanski-score the inter-observer correlations
were 0.996 for RM and 0.999 for M2. The intra-obser-
ver correlations were ≥ 0.996 for all measurements.
Additional file 2 provides the Bland-Altman-plots.
At baseline, Poznanski-scores were comparable to
those in healthy children, with a median Poznanski-score
of − 0.45 (− 0.74–0.45). Over time, overall no significant
change in Poznanski-score, unadjusted nor after adjust-
ing for age and symptom duration, was observed, and
there were no differences between the 3 arms (see Figs. 3
and 4 for observed and predicted changes in Poznanski-
score, BA and BMD Z-scores per arm). The outlier in
Fig. 3b with a high Poznanski-score (Z-score 3,9) is a
competing mountain-biker.
Bone age
At baseline, the mean BA Z-score was 0.04 (-0.58; 0.67)
for the entire group, similar to the normal reference
population. Baseline scores in arm 3 were significantly
lower than in arms 1 and 2, but still within the normal
range (1 SD from 0). Over time there was a decrease in
BA in arm 3 (arm 3 versus arm 1 p = 0.024, β = 0.014
(95%CI -0.002; 0.027) which remained within the normal
range (Fig. 4).
Bone mineral density
At baseline, the mean BMD Z-score was − 0.65 (− 0.90;
− 0.40) for the entire group, with statistically significantly
lower baseline BMD in arm 3 compared to the normal
reference population. Over time the BMD, adjusted or
unadjusted for symptom duration, remained unchanged
in arm 1, showed a trend for increase in arm 2 and sig-
nificantly increased in arm 3 (p < 0.001 for arm 3 versus
arm 1, β = − 0.028 (95% CI -0.043; − 0.013).
Tables with detailed results of the LMM of the
Poznanski-score, BA and BMD are presented in
Additional file 3. Results comparing all left with all
right hands, both at baseline and during follow-up,
were not statistically different for Poznanski-score (p =
0.809, BA (p = 0.825) nor BMD (p = 0.404). Six patients
with radiographs never had clinical inflammation of wrists.
Sensitivity analyses excluding these patients showed similar
results to the main analysis (Additional file 4A). Since
we included n = 7 patients with oligoarthritis and n = 3
patients with psoriatic arthritis, numbers are too small
to analyse these groups separately. Sensitivity analysis
of the polyarticular subgroup only, showed similar re-
sults (Additional file 4B).
Effect meanJADAS10-score over time on Poznanski, Bone
Age and BMD
To investigate whether mean JADAS10-score over time
correlated with any of the radiological outcomes, we
Fig. 2 Poznanski measurements used to determine the RM/M2
score. RM = radiometacarpal length; M2 = length of the
second metacarpal
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have performed separate analyses for the 3 radiological
outcome measures. Mean JADAS10-score over time did
not influence Poznanski score, [β (95% CI) 0.0010 (−
0.00038; 0.0024), p = 0.154], Bone Age [β (95% CI) -0.00017
(− 0.0018; 0.0014), p = 0.84] or BMD [β (95% CI) 0.00069
(− 0.0012; 0.0026), p = 0.48]. Tables and graphs from this
analysis are reported in Additional file 4C.
Discussion
Our study is the first to describe longitudinal radio-
logical outcomes of a tightly controlled treat-to-target
approach, aimed at inactive disease during 24 months of
treatment, in recent onset poly- and oligoarticular JIA
patients. Despite a symptom duration of mean (SD) 7.6
(4.9) months and a JADAS-10 of 18.7 (5.6), at baseline,
we found no significant differences in Poznanski-score
and BA (as measured by the BoneXpert-method) of wrist
radiographs compared to healthy children. Only in arm
3 BMD as measured by the BoneXpert-method was sig-
nificantly lower than the normal reference population.
After 24 months of treatment, there was no deterioration
in any of the scores and in arm 3 BMD had statistically
significantly improved. Mean JADAS10-scores over time
were not associated with any of the radiological out-
comes in this analysis.
Combined with rapid suppression of symptoms of ac-
tive arthritis, prevention of damage is an important
treatment goal in JIA. Damage has been most notably
found in patients with longstanding and/or seropositive
polyarticular JIA, but may also occur in seronegative
polyarticular JIA and oligoarticular JIA [19–21]. As has
been shown in rheumatoid arthritis, it is thought likely
that, also in JIA, damage progression is driven by inflam-
matory processes. Assessing damage in patients who are
in very different phases of joint development can be
challenging. In growing children, cartilage thinning, de-
layed or accelerated growth and reduced bone mineral
density rather than bony erosions and joint space nar-
rowing may indicate damage. Decreased bone age often
reflects delayed bony maturation in JIA [22, 23] but also
Table 1 Baseline characteristics of the patients selected from the original 3 arms
Arm 1
Sequential
monotherapy
(n = 21/31)
Arm 2
Combo MTX
+ 6wks Prednisone
(n = 18/32)
Arm 3
Combo MTX
+ etanercept
(n = 21/29)
P
Age (years), median (IQR) 8.2 (4.1;10.2) 7.9 (5.7;11.7) 6.2 (3.8;10.4) < 0.001
Symptom duration (months), median (IQR) 7.8 (4.2;11.3) 5.3 (2.6;6.1) 8.5 (4.2;12.1) 0.015
ANA pos, n (%) 8 (38) 6 (33) 8 (28) 0.94
Female, n (%) 14 (66.7) 9 (50) 15 (71.4) 0.36
JIA Category: 0.90
Oligo, n (%) 3 (14.3) 2 (11.1) 2 (9.5)
Poly, n (%) 17 (81) 14 (77.8) 18 (85.7)
Psoriatic, n (%) 1 (4.8) 1 (5.6) 1 (4.8)
VAS physician, mean ± SD (mm) 43.6 ± 15.7 54.0 ± 17.0 52.9 ± 17.5 0.44
VAS patient/parent, mean ± SD (mm) 53 ± 17.1 56.8 ± 23.4 55.2 ± 24.9 0.31
CHAQ, mean ± SD 0.95 ± 0.7 1.1 ± 0.6 1.0 ± 0.6 0.88
No. active joints, median (IQR) 6 (4.5;14.5) 8 (5.8;11.5) 8 (5.5;11.5) 0.56
No. limited joints, median (IQR) 2 (0.5;4) 1.5 (0.8;3.3) 3 (2.5;5.5) 0.68
ESR, median (IQR) (mm) 6 (2;12) 6 (3.5;32) 9 (6;31.5) 0.28
JADAS-10 mean ± SD (0–40) 16.7 ± 4.5 19.6 ± 5.1 19.1 ± 5.8 0.24
Z-score Poznanski median (IQR)1 −0.45 (− 0.70;0.56) −0.19 (− 0.57;0.68) −0.61 (− 0.82;0.17) 0.056
Z-score Bone Age mean (CI)2 −0.38 (− 0.88;0.11) 0.51 (0.28;0.74) −0.43 (− 0.82;−0.04) 0.001
Z-score BMD mean (CI)3 −0.44 (− 0.84;−0.04) −0.39 (− 0.93;0.15) −1.08 (− 1.48;−0.68) 0.03
Wrist arthritis, inclusion (%) 19/21 (90) 14/18 (78) 18/21 (86)
Wrist arthritis, follow-up (%) 17/21 (81) 14/18 (78) 18/21 (86)
Wrist arthritis, inclusion or follow-up (%) 21/21 (100) 14/18 (78) 19/21 (90)
JIA juvenile idiopathic arthritis, oligo oligoarticular JIA, poly polyarticular JIA, IQR interquartile range, VAS Visual Analogue Scale, ANA antinuclear antibody, RF
rheumatoid factor, SD standard deviation, CI confidence interval, CHAQ Child Health Assessment Questionnaire, No number, ESR Erythrocyte Sedimentation Rate,
JADAS Juvenile Arthritis Disease Activity Score, BMD Bone Mineral Density, BA Bone Age (both using BoneXpert method) Z-scores were based on all available
radiographs, including left and right hand radiographs. 1: n = 35 in arm 1, n = 25 for arm 2, n = 31 for arm 3; 2: n = 16 for arm 1, n = 18 for arm 2 and n = 18 for
arm 3, 3: n = 33, n = 25 for arm 2 and n = 32 for arm 3. n = amount of X-rays
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increased focal bone maturation can be a result of joint
inflammation [15].
Compared to older cohorts [12, 24] or recent cohorts
with longer disease duration [17], we found little damage at
baseline in this cohort with recent-onset disease. Since we
did not include patients with RF-positive polyarticular JIA,
this could be a mildly affected cohort although initial
JADAS10 scores were similar to other cohorts [25]. In
addition we found no significant damage progression. This
is possibly due to our strategy of tightly controlled treat-
ment-to-target aiming at inactive disease in all 3 treatment
arms, resulting in rapid suppression of inflammation in
Fig. 3 a,b,c – Poznanski-score depicted in Z-scores of RM/M2 ratio. a represents patients in arm 1, b represents patients in arm 2, c represents
patients in arm 3. d,e, f- Bone Age depicted in Z-score. d represents patients in arm 1, e represents patients in arm 2, f represents patients in arm
3. g,h,i. Bone Mineral Density depicted in Z-scores. g represents patients in arm 1, h represents patients in arm 2, i represents patients in arm 3.
Each graph line represents one individual patient from baseline to follow-up. Each dot represents one patient with a single radiograph available
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most patients, without significant differences between the
strategy-arms after 24months. Only in arm 3 there was an
initial greater clinical improvement [10]. We cannot rule
out an additional positive effect of use of etanercept, in all
patients in arm 3, and in many in arms 1 and 2 after they
failed to achieve remission on initial treatment with metho-
trexate (with or without temporary prednisone). Previous
studies suggest that treatment with methotrexate cannot
prevent joint damage progression whereas use of biologic
DMARDs (used as initial treatment in our arm 3) may be
more successful, although data are limited [26, 27]. Apart
from strategy, we did not find an effect of mean JADAS10-
score over time, possibly in all patients due to rapid sup-
pression of inflammation, therefore inhibiting the disease to
have time to create damage.
To score differences in potentially little damage, we
needed a sensitive scoring method. Conventional radiog-
raphy has proven to be a useful modality to monitor
wrist damage of JIA patients [2, 4, 5, 13, 28–31]. Several
methods, like the Dijkstra-score [31], modified Sharp
van der Heijde-score [5, 19] the modified Larsen-score
[4, 32] and the Steinbrocker-scale [33, 34] have been de-
veloped to evaluate radiographic damage to the osteo-
chondral structures of the wrist and hand. The Dijkstra
composite-score is limited in the grading of changes for
severity over time [35]. We stopped using the modified
Sharp van der Heijde for pediatric assessment of joint
damage [5] as it proved too difficult to uniformly score
subtle changes in joint space narrowing, bony erosions
and bone deformity, as was recognized previously [35].
Magnetic resonance imaging (MRI) and ultrasound (US)
are suitable for monitoring disease activity for evaluating
treatment response, and may also detect damage [36].
However, interpretation of MRI findings of the osteo-
chondral domain in JIA patients is challenging due to
characteristics of the growing skeleton, in particular in
hand and wrist joints. Bone marrow edema and bony de-
pressions are also frequently seen on MRI in wrists of
healthy children [37–40]. Until now, no optimal method
has been found to differentiate pathological and stan-
dardized age-specific findings in healthy children on
MRI and US which limits their use to accurately assess
damage and damage progression in the wrist of JIA
patients.
The Poznanski-score, which measures relative carpal
length on radiographs of the wrist, is able to detect devi-
ating growth in absence of distinct joint space narrowing
or erosions [13]. A disadvantage of the Poznanski-score
is that it requires open growth plates, which caused in-
eligibility in 14 of our patients, and unreliability in case
of carpometacarpal erosions which hampers discriminat-
ing bony ends, which did not occur in our cohort. In
addition, we used the relatively new BoneXpert method
to score Bone Age and BMD, which, compared to a
healthy reference population, can indicate damage due
to inflammation.
The BoneXpert method, based on digital X-ray radio-
grammetry (DXR), allows to determine the Bone Age
Fig. 4 a: Predicted Z-score RM/M2 over time, b: Predicted Z-score
Bone Age over time, c: Predicted Z-score BMD over time. All
predictions are from Linear Mixed Models, corrected for age and
symptom duration for Poznanski score, corrected for symptom
duration for BA and BMD. BA = Bone Age, BMD= Bone Mineral Density
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and BMD compared to a normal reference population,
at lower costs and with lower radiation than manually
comparing the hand radiograph with images in the atlas
by Greulich and Pyle [16] and than measuring BMD by
Dual Energy X-ray Absorptiometry (DXA) [41]. The
BMD measurement by BoneXpert is corrected for the
size of the cortical bones to compensate for the high
variation in stature of growing children, in contrast to
DXA. Previous studies have reported on delayed bone
maturation as reflected by negative Z-scores for Bone
Age [12, 17]. These studies had included patients with
more severe or longstanding active disease. However,
Borzutzky and others have warned previously, that de-
termining bone age can be challenging in JIA due to ac-
celerated maturation [15, 42].
In JIA patients, BMD is often reduced [12, 17, 43–45].
BMD was significantly lower at baseline in arm 3 (− 1.1
SD, (− 1.48; − 0.68)). This could indicate longstanding or
more severe disease. Indeed symptom duration in arm 3
was slightly longer than in arms 1 and 2, although JADAS-
10 scores at baseline were similar in the 3 arms. Possibly as
a result of rapid and sustained suppression of inflammation,
BMD improved significantly over time in arm 3. A previous
study also reported improvement of BMD after therapy
[45]. It is speculated that this improvement is due to the
anti-inflammatory effect of DMARD treatment [46],
more specifically due to etanercept [47, 48]. However,
no comparison cohort is available to prove that the
treatment-to-target approach is responsible for a better
radiological outcome.
Future studies are needed to delineate the effect of the
treatment-to-target concept on improving bone health
as reflected by bone maturation and BMD in JIA.
Our study has some limitations. Although comparable
with other studies [2, 26, 49] in children with JIA, we
had a relatively small sample size (n = 60), and we may
have lacked power to detect small differences. In previ-
ous studies, results were based on clinically inflamed
wrists only. Since we have examined also 6 patients with
wrist radiographs of unaffected wrists, in this study we
may have underestimated damage, although sensitivity
analyses excluding patients who never had any clinical
wrist arthritis over 24 months showed similar results. It
remains to be determined whether joint damage is
mainly due to local inflammation or (also) to systemic
inflammatory processes of JIA.
Due to our choice of scoring methods, patients were
excluded who had closed growth plates. Also we disre-
garded results of radiographs made outside the selected
time frame. Follow-up time was relatively short compared
to previous cohorts. However, often radiographic damage is
expected to occur within the first one or two years [2]. Fi-
nally, determination of bone health by BoneXpert software
needs further validation, including further comparison with
existing methods for the determination of BMD in
JIA patients [41, 50, 51].
Conclusions
We conclude that in our cohort of patients with recent-
onset JIA who were treated-to-target aiming at inactive
disease, wrist-radiographs showed neither damage ac-
cording to Poznanski at baseline, nor progression after 2
years. Bone age was within normal values at baseline
and after follow-up. In arm 3, BMD was lower at base-
line but improved significantly towards normalization
during treatment. We propose that with earlier start of
treatment and treatment to target, the focus of current
treatment regimens shifts to damage prevention rather
than suppression of damage progression. This will likely
also prevent long-term disability. Future JIA-cohorts
with more patients and longer follow-up are warranted
to confirm these promising results for children with JIA.
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